Abbott (NYSE:ABT) today announced a significant regulatory milestone that could make common medical procedures easier for people with diabetes.
雅培公司（NYSE:ABT）今天宣布了一项重要的监管里程碑，它将使糖尿病患者更容易进行常见的医疗程序。
Our sister site, Drug Delivery Business News, reports today that the FDA cleared the removal of the imaging contradiction for the FreeStyle Libre 2 and 3 continuous glucose monitors (CGMs) for procedures like X-rays, CT scans and MRIs. Abbott said it makes its systems the first and only patient-applied CGM sensors approved for these screenings.
我们的姊妹网站《给药商业新闻》（Drug Delivery Business News）今天报道，美国食品及药物管理局（FDA）批准取消
FreeStyle Libre 2 和 3 血糖监测仪（CGM）在 X 射线、CT 扫描和核磁共振成像（MRI）等程序中的成像限制。雅培表示，这使其系统成为首款也是唯一一款获准用于这些检查的患者应用 CGM 传感器。
FreeStyle Libre 2 和 3 血糖监测仪（CGM）在 X 射线、CT 扫描和核磁共振成像（MRI）等程序中的成像限制。雅培表示，这使其系统成为首款也是唯一一款获准用于这些检查的患者应用 CGM 传感器。
Imaging procedures often come as part of diabetes care, Abbott said, especially as diabetes can cause a number of medical complications. The company rigorously tested its Libre 2 and 3 sensors to ensure they remain effective after radiologic procedures. This FDA clearance comes with no changes made to the sensor, too.
雅培公司表示，成像程序通常是糖尿病护理的一部分，尤其是糖尿病会引起一系列医疗并发症。该公司对 Libre 2 和 3 传感器进行了严格测试，以确保它们在放射治疗后仍然有效。此次通过 FDA 认证，传感器也未做任何改动。